Skip to main content

Advertisement

SpringerLink
Log in

Radioiodination and preclinical evaluation of 4-benzyl-1-(3-[125I]-iodobenzylsulfonyl)piperidine as a breast tumor imaging tracer in mouse

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

4-Benzyl-1-(3-iodobenzylsulfonyl)piperidine, 4-B-IBSP, has shown high-binding affinity to both sigma (σ) receptors in our previous work. In current study, radiolabeling and preclinical evaluation of 4-benzyl-1-(3-[125I]-iodobenzylsulfonyl)piperidine, 4-B-[125I]IBSP, in human ductal breast carcinoma (T47D) cells and in breast adenocarcinoma-bearing BALB/c mice are described.

Methods

Radioiodination of this new σ ligand was performed by a palladium-catalyzed stannylation approach followed by oxidative iododestannylation reaction using Iodo-Gen. Competition-binding assays for binding of 4-B-[125I]IBSP to guinea pig brain membranes and to T47D cells were performed with known σ ligands. The selectivity and binding characteristics (B max and K d) were analyzed. In vitro stability and in vivo blood metabolism studies were also evaluated. Moreover, biodistribution studies were performed in normal and into the tumor-bearing mice at interval time points post-injection (p.i.). Both in vitro and in vivo blockade experiments were done in the presence of the σ receptors blocking agents.

Results

Radioiodinated ligand was obtained in high yield and high specific activity. The σ inhibition constants (K i, nM) for 4-(3-iodobenzyl)-1-(benzylsulfonyl)piperazine (4-IBBSPz), (+)-pentazocine, haloperidol, DTG, and 4-B-IBSP were 1.37 ± 0.19, 3.90 ± 0.77, 2.69 ± 0.33, 30.62 ± 2.01, and 0.61 ± 0.05, respectively. 4-B-[125I]IBSP bound to σ receptor sites preferably to very high-affinity binding sites on T47D cells. The radioligand showed acceptable in vitro and in vivo stabilities in the blood pool. However, in vivo biodistribution studies in normal Swiss albino mice revealed fast clearance of 4-B-[125I]IBSP from blood and the other normal organs. Biodistribution experiments of 4-B-[125I]IBSP in breast adenocarcinoma tumor-bearing BALB/c mice showed a relatively high tumor uptake at 30 min p.i. (4.13 ± 0.95) that reaches to 1.57 ± 0.24 even after 240 min p.i. A pre-injection of 4-B-IBSP and haloperidol with 4-B-[125I]IBSP resulted in 36–57% decrease in activity in the tumor, liver, and brain at 60 min p.i.

Conclusions

The high affinity of 4-B-[125I]IBSP to σ receptor-binding sites, its relatively high uptake, and preferential retention in the tumor as well as an increasing trend observed in the tumor to blood and in the tumor to muscle ratios suggests that an iodine-123 labeled counterpart, 4-B-[123I]IBSP, would be a promising σ radioligand for pursuing further studies to assess its potential for breast tumors imaging with SPECT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10, 2015. http://globocan.iarc.fr. Accessed 10 March 2015

  2. Bénard F, Turcotte É. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res. 2005;7:153–62.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Penuelas I, Dominguez-Prado I, Garcia-Velloso MJ, Marti-Climent JM, Rodriguez-Fraile M, Caicedo C, et al. PET tracers for clinical imaging of breast cancer. J Oncol. 2012;2012:1–9.

    Article  Google Scholar 

  4. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m-methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med. 1997;24:1138–45.

    CAS  PubMed  Google Scholar 

  5. Caveliers V, Everaert H, John CS, Lahoutte T, Bossuyt A. Sigma receptor scintigraphy with N-[2-(1′-piperidinyl)ethyl]-3-[123I]iodo- 4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med. 2002;43:1647–9.

    CAS  PubMed  Google Scholar 

  6. Nachar O, Rousseau JA, Ouellet R, Rioux A, Lefebvre B, Ali H, et al. Scintimammography with 11β-Methoxy-(17α,20Z)-[123I]Iodovinylestradiol: a complementary role to [99mTc]Methoxyisobutyl isonitrile in the characterization of breast tumors. J Nucl Med. 2000;41:1324–31.

    CAS  PubMed  Google Scholar 

  7. Martin WR, Eades C, Thompson J, Huppler R, Gilbert P. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exper Therap. 1976;197:517–32.

  8. Abou-Gharbia M, Ablordeppey SY, Glennon RA. Sigma receptors and their ligands: the sigma enigma. Annu Rep Med Chem. 1993;28:1–10.

    Article  CAS  Google Scholar 

  9. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55:408–13.

    CAS  PubMed  Google Scholar 

  10. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 1991;51:6558–62.

    CAS  PubMed  Google Scholar 

  11. Aydar E, Palmer CP, Djamgoz MB. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res. 2004;64:5029–35.

    Article  CAS  PubMed  Google Scholar 

  12. Aydar E, Onganer P, Perrett R, Djamgoz MB, Palmer CP. The expression and functional characterization of sigma 1 receptors in breast cancer cell lines. Cancer Lett. 2006;242:245–57.

    Article  CAS  PubMed  Google Scholar 

  13. van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH, Dierckx RA. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des. 2010;16:3519–37.

    Article  PubMed  Google Scholar 

  14. van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH, Dierckx RA. Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim Biophys Acta. 2015;1848:2703–14.

    Article  PubMed  Google Scholar 

  15. Hou C, Tu Z, Robert R, Kung HF, Kung M-P. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl Med Biol. 2006;33:203–9.

    Article  CAS  PubMed  Google Scholar 

  16. Mach RH, Smith CR, Al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. σ2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997;57:156–61.

    CAS  PubMed  Google Scholar 

  17. Akhter N, Shiba K, Ogawa K, Kinuya S, Nakajima K, Mori H. In vivo characterization of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino] cyclohexanol as a potential σ-1 receptor imaging agent. Nucl Med Biol. 2007;34:697–702.

    Article  CAS  PubMed  Google Scholar 

  18. John CS, Gulden ME, Li J, Bowen WD, McAfee JG, Thakur ML. Synthesis In vitro binding, and tissue distribution of radioiodinated 2-[125I]N-(N-Benzylpiperidin-4-yl)- 2-Iodo benzamide, 2-[125I]BP: a potential σ receptor marker for human prostate tumors. Nucl Med Biol. 1998;25:189–94.

    Article  CAS  PubMed  Google Scholar 

  19. John CS, Vilner BJ, Bowen WD. Synthesis and Characterization of [125I]-N-(N- Benzylpiperidin-4-yl)-4-iodobenzamide, a new σ receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells. J Med Chem. 1994;37:1737–9.

    Article  CAS  PubMed  Google Scholar 

  20. John CS, Bowen WD, Fisher SJ, Lim BB, Geyer BC, Vilner BJ, Wahl RL. Synthesis in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1′- Piperidinyl)ethyl]-3-[125I]Iodo-4-methoxybenzamide (P[125I]MBA) for Imaging Breast Cancer. Nucl Med Biol. 1999;26:377–82.

    Article  CAS  PubMed  Google Scholar 

  21. John CS, Vilner BJ, Gulden ME, Efange SMN, Langason RB, Moody TW, Bowen WD. Synthesis and pharmacological characterization of 4-[125I]-N-(N-Benzylpiperidin- 4-yl)-4-iodobenzamide: a high affinity σ receptor ligand for potential imaging of breast cancer. Cancer Res. 1995;55:3022–7.

    CAS  PubMed  Google Scholar 

  22. John CS, Lim BB, Vilner BJ, Geyer BC, Bowen WD. Substituted halogenated arylsulfonamides: a new class of σ receptor binding tumor imaging agents. J Med Chem. 1998;41:2445–50.

    Article  CAS  PubMed  Google Scholar 

  23. John CS, Gulden ME, Vilner BJ, Bowen WD. Synthesis in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-Iodophenyl)Ethyl]-N-Methyl-2-(1-Piperidinyl) ethylamine: A high-affinity ligand for imaging sigma receptor positive tumors. Nucl Med Biol. 1996;23:761–6.

    Article  CAS  PubMed  Google Scholar 

  24. Hirata M, Mori T, Umeda T, Abe T, Yamamoto T, Ohmomo Y. Evaluation of radioiodinated 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(2-iodophenylpropyl)piperazine as a tumor diagnostic agent with functional sigma receptor imaging by single photon emission computed tomography. Biol Pharm Bull. 2008;31:879–83.

    Article  CAS  PubMed  Google Scholar 

  25. Garner SE, Kung M-P, Foulon C, Chumpradit S, Kung HF. [125I](S)-trans-7-OH- PIPAT: a potential SPECT imaging agent for sigma binding sites. Life Sci. 1994;54:593–603.

    Article  CAS  PubMed  Google Scholar 

  26. Sadeghzadeh M, Sheibani S, Ghandi M, Johari Daha F, Amanlou M, Arjmand M, et al. Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands. Eur J Med Chem. 2013;64:488–97.

    Article  CAS  PubMed  Google Scholar 

  27. Council B. Guidelines on the use of living animals in scientific investigations:biological council. London: Institute of Biology; 1987.

    Google Scholar 

  28. Akgӥn E, Portoghese PS, Sajjad M, Nabi HA. Synthesis and 124I-labeling of m-iodophenylpyrrolomorphinan as a potential PET imaging agent for delta opioid (DOP) receptors. J Label Compd Radiopharm. 2007;50:165–70.

    Article  Google Scholar 

  29. Markwell MAK, Fox CF. Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochem. 1978;17:4807–17.

    Article  CAS  Google Scholar 

  30. Bradford MM. A rapid, sensitive. method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.

    Article  CAS  PubMed  Google Scholar 

  31. Alizadeh AM, Azizian S, Fayazi HR, Mousavi M-S, Nabavi SA. Mouse spontaneous mammary adenocarcinoma as a suitable model of breast cancer in Iran. Basic &amp. Clin Cancer Res. 2011;3:30–3.

    Google Scholar 

  32. Ablordeppey SY, Fischer JB, Law H, Glennon RA. Probing the proposed phenyl-A region of the sigma-1 receptor. Bioorg Med Chem. 2002;10:2759–65.

    Article  CAS  PubMed  Google Scholar 

  33. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol Mol Pharmacol Sect. 1994;268:9–18.

    Article  CAS  Google Scholar 

  34. Sadeghzadeh M, Johari Daha F, Sheibani S, Erfani M. Radioiodination of 4-benzyl-1- (3-iodobenzylsulfonyl)piperidine, 4-(3-iodobenzyl)-1-(benzylsulfonyl)piperazine and their derivatives via isotopic and non-isotopic exchange reactions. J Radioanal Nucl Chem.2014;302, 1119–25.

  35. Mésangeau C, Amata E, Alsharif W, Seminerio MJ, Robson MJ, Matsumoto RR, et al. Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. Eur J Med Chem. 2011;46:5154–61.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002;62:313–22.

    CAS  PubMed  Google Scholar 

  37. Wolfe SA Jr, Ha BK, Whitlock BB, Saini P. Differential localization of three distinct binding sites for sigma receptor ligands in rat spleen. J Neuroimmunol. 1997;72:45–58.

    Article  CAS  PubMed  Google Scholar 

  38. Choi S-R, Yang B, Plössl K, Chumpradit S, Wey S-P, Acton PD, Wheeler K, Mach RH, Kung HF. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol. 2001;28:657–66.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Financial support by Radiation Application Research School of the Nuclear Science and Technology Research Institute is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Radiation Application Research School, Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 11365-3486, Tehran, Iran

    Masoud Sadeghzadeh, Behrouz Alirezapour, Ghorban Ali Charkhlooie, Maryam Keshavarz Baghery & Amir Khorouti

Authors
  1. Masoud Sadeghzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Behrouz Alirezapour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ghorban Ali Charkhlooie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maryam Keshavarz Baghery
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amir Khorouti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masoud Sadeghzadeh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sadeghzadeh, M., Alirezapour, B., Charkhlooie, G.A. et al. Radioiodination and preclinical evaluation of 4-benzyl-1-(3-[125I]-iodobenzylsulfonyl)piperidine as a breast tumor imaging tracer in mouse. Ann Nucl Med 31, 335–346 (2017). https://doi.org/10.1007/s12149-017-1161-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-017-1161-8

Keywords

Search

Navigation